On the safety assurance of cell processing carried out in medical institutions for autologous immuno-cell therapy

Human Cell
Kohji Egawa

Abstract

Autologous immuno-cell therapy of cancer has been mainly carried out in university hospitals as therapeutic research. Recently, private clinics specialized in the therapy are appearing in Japan. At present, cell processing necessary for the therapy is carried out not by pharmaceutical companies but by medical institutions. In this case, there is no government regulation on the safety assurance of the procedure. For the wholesome popularization of the therapy, however, it is of utmost importance to carry out cell processing under safety assurance, which could be done as self-regulation by medical institutions. A guideline for safety assurance tentatively set by Seta Clinic Group, which is a group of clinics specialized in the therapy and its usefulness in protecting patients from hazardous accidents are shown.

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.